Happy Holidays Biotech Reading List

You can’t have value-based drug pricing without value
Frank David (Pharmagellan)

Ebola, Ethics, And The New Normal Of Scary Germs
Matthew Herper (Forbes)

Expansion of Expanded Access? Federal Right to Try Legislation is Introduced
James Shehan (FDA Law Blog)

The End of the Hard Switch? What the Judge Says About an Actavis Tactic
Ed Silverman (Pharmalot / WSJ)

Delving Into Morass of Insider Trading
James Stewart (New York Times)

My thoughts about a ridiculous take on biotech social media
Brad Loncar (Loncar Blog)

Beta-Amyloid: The Emperor Really Does Have No Clothes
David Grainger (Forbes)